anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this prospective, randomized study is to evaluate the effects of point-of-care testing of NT-proBNP in patients presenting with acute dyspnea to the Emergency Medical Service (EMS).Patients will be enrolled in the Emergency Medical Services of participating German hospitals (Klinikum Nürnberg, Klinikum Fürth, Universitätsklinikum Jena). To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the exclusion criteria.

Patients with acute dyspnea randomized to the POCT group will get a NT-proBNP-POCT measurement in the EMS. The emergency physician of the EMS will decide to apply predefined treatment strategies according to the resulting working hypothesis. Patients with acute dyspnea randomized to the standard care group will NOT get NT-proBNP measurement at the scene. The emergency physician of the ED will construct the working hypothesis following current treatment recommendations. The major focus of the study is to initiate treatment of heart failure as early as possible.
Dendritic cells (DCs) are the most specialized antigen-presenting cells, and lymph nodes (LNs) play an important role in the DC-mediated T-cell response. We evaluated the infiltration of CD1a-positive DCs (CD1a-DCs), i.e., immature DCs, and S100-positive dendritic cells (S100-DCs), a mixture of immature and mature DCs, in 73 cases of laryngeal cancer and its regional LNs. Among them, 31 patients underwent radiotherapy (RT) or chemoradiotherapy (CRT) prior to surgery. No significant difference was found for CD1a-DC infiltration in the primary tumors, metastatic LNs and non-metastatic LNs, while S100-DCs were significantly fewer in number in the primary tumors and metastatic LNs compared to non-metastatic LNs. The cases which showed a high infiltration of S100-DCs in the metastatic LNs appeared to show a favorable prognosis, although statistical significance was not reached. In the RT/CRT group, the infiltration of the CD1a-DCs and S100-DCs was less in the primary tumors and metastatic LNs compared to the treatment-naive group. Conversely, the RT/CRT group showed higher CD1a-DC and S100-DC numbers in the non-metastatic LNs compared to the treatment-naïve group. Thus, DC maturation in metastatic LNs plays an important role in tumor immunity in laryngeal cancer, and the infiltration of DCs into the primary tumor and metastatic LNs is impaired by RT/CRT.
The invention provides a SARS-ConV-2 virus S protein membrane outside N end domain high targeting recombinant protein and subunit vaccine thereof, the nucleotide sequence of the encoding recombinant protein is selected from the group consisting of SEQ ID NO: 8. SEQ ID NO: 9. SEQ ID NO: 11. SEQ ID NO: 14, one of which is shown in fig. 14; the novel coronavirus subunit vaccine comprises the recombinant protein and a pharmaceutically acceptable adjuvant. The invention screens the surface antigenic determinant of the S protein extramembranous domain, finds the gene sequence of the Sn1-Sn7 peptide segment which can stimulate cells to generate strong immune response, carries out codon optimization, clones the gene sequence to a plasmid vector containing a diphtheria toxin T structure, secretes, expresses and purifies the gene sequence, and the obtained recombinant protein can induce specific cell reaction through experimental verification, is safe and efficient, and has good development and application prospects.
Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
Pilates Reformer (PR) is one of the most popular types of exercise worldwide and is considered a gentle and safe method for untrained and overweight people. The PR training approach has been found to contribute positively to various health conditions (vascular function, blood pressure, physical fitness, musculoskeletal problems), improving the quality of life and mental well-being of the participants. At the same time, it seems that it can have a positive effect on the lipid profile and other biochemical markers such as insulin and fasting glucose. Furthermore, muscle strengthening training with PR equipment provides better levels of mobility, increasing active range of motion, and also provides greater pelvic and trunk stability for both adult and middle-aged participants.

This study is designed to investigate the physiological and metabolic burden of a muscle-strengthening session with PR equipment in 20 pre-menopausal and physically inactive women with a body mass index (BMI) of 18-24, 99 \& 25.01-39.9, as well as to determine the contribution of energy systems (mitochondrial, glycolytic) during and after the exercise. Each training session will last approximately 60 minutes, will be led by at least one trainer, and will include a warm-up of 7-10 minutes, muscle strengthening and mobility exercises of 35 minutes, and a recovery of 5 minutes. Anthropometric indicators, dietary intake, resting heart rate, blood lactate, resting metabolic rate, muscle soreness, rate of perceived exertion, blood pressure, and performance measurements will be measured at baseline. The metabolic cost during PR training session will be estimated from heart rate, blood lactate, resting oxygen uptake, exercise oxygen uptake, and excess post-exercise oxygen consumption measurements using a portable gas analyzer. After the PR training session will be measured the rate of perceived exertion, blood pressure, blood lactate, and muscle soreness levels.
Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
The invention relates to nucleic acid molecules coding for (poly)peptides associated with apoptosis. In preferred forms of embodiment, the (poly)peptides induce or inhibit apoptosis. The invention also relates to (poly)peptides coded by said nucleic acids, vectors containing said nucleic acid molecules, and hosts transformed by said nucleic acid molecules. Preferably, the hosts are transgenic non-human mammals. The invention further relates to methods for identifying test substances which directly or indirectly activate or inhibit the inventive (poly)peptides, and to methods for improving such test substances. Furthermore, the invention relates to methods for producing pharmaceuticals or medical products in which the identified or improved test substance is formulated with a pharmaceutically acceptable carrier or diluting agent, and to pharmaceuticals which can be used to induce or inhibit apoptosis and to treat associated diseases.
Methods of producing picornavirus-like particles (PVLPs) in plants are provided. The method comprises introducing a first nucleic acid and a second nucleic acid into a plant, a part of a plant, or a plant cell. The first nucleic acid comprises a first regulatory region active in plants operably linked to a nucleotide sequence encoding a picornavims polypeptide. The second nucleic acid comprises a second regulatory region active in plants operably linked to a nucleotide sequence encoding one or more picornavims proteases. Growing the plant, the portion of the plant, or the plant cell under conditions that allow expression of the nucleic acid, thereby producing the PVLP. PVLPs comprising the polypeptides are also provided.
Genetic factors confer risks for depression. Understanding the neural endophenotypes, including brain morphometrics, of genetic predisposition to depression would help in unraveling the pathophysiology of depression. We employed voxel-based morphometry (VBM) to examine how gray matter volumes (GMVs) were correlated with the polygenic risk score (PRS) for depression in 993 young adults of the Human Connectome Project. The phenotype of depression was quantified with a DSM-oriented scale of the Achenbach Adult Self-Report. The PRS for depression was computed for each subject using the Psychiatric Genomics Association Study as the base sample. In multiple regression with age, sex, race, drinking severity, and total intracranial volume as covariates, regional GMVs in positive correlation with the PRS were observed in bilateral hippocampi and right gyrus rectus. Regional GMVs in negative correlation with the PRS were observed in a wide swath of brain regions, including bilateral frontal and temporal lobes, anterior cingulate cortex, thalamus, lingual gyri, cerebellum, and the left postcentral gyrus, cuneus, and parahippocampal gyrus. We also found sex difference in anterior cingulate volumes in manifesting the genetic risk of depression. In addition, the GMV of the right cerebellum crus I partially mediated the link from PRS to depression severity. These findings add to the literature by highlighting 1) a more diverse pattern of the volumetric markers of depression, with most regions showing lower but others higher GMVs in association with the genetic risks of depression, and 2) the cerebellar GMV as a genetically informed neural phenotype of depression, in neurotypical individuals.
Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of screening with a 2 hour glucose tolerance test at 6-12 weeks postpartum.
BACKGROUND: Antibiotics have been reported as an efficient and safe treatment option for uncomplicated acute appendicitis without an appendicolith diagnosed using computed tomography (CT). The aim of this study was to assess the association of a CT-diagnosed appendicolith and its characteristics with appendicitis severity.
METHODS: A large prospective patient cohort with suspected acute appendicitis enrolled between April 2017 and November 2018 was retrospectively reviewed. The initial analysis evaluated the association of a CT-diagnosed appendicolith with complicated acute appendicitis; then, based on the availability of CT images, a subset of patients was analysed for the correlation of appendicolith characteristics with appendicitis severity. The final appendicitis assessment (uncomplicated or complicated-including perforation, gangrene, an abscess, or a tumour) was determined for all patients.
RESULTS: Out of 3512 eligible patients, 3085 patients with appendicitis were selected and 380 patients with an appendicolith and with a CT image available for reassessment were included. Out of the 3085 patients with CT-diagnosed acute appendicitis, 1101 (35.7%) patients presented with both acute appendicitis and an appendicolith and, out of these, 519 (47.1%) had complicated acute appendicitis. In the patients without an appendicolith (1984 patients), 426 (21.5%) had complicated appendicitis (P < 0.001). Re-evaluation of CT images for 380 patients showed that a larger appendicolith diameter (OR = 1.15 (95% c.i. 1.06 to 1.25); P < 0.001), appendicolith location at the base of the appendix (55.1% versus 44.9%; P = 0.008), and heterogeneous appendiceal wall enhancement around the appendicolith (68.4% versus 31.6%; P < 0.001) were associated with an increased risk of complicated acute appendicitis.
CONCLUSION: The presence of an appendicolith in patients with acute appendicitis is correlated with the risk of complicated appendicitis. This risk is further increased by a larger appendicolith diameter or appendicolith location at the base of the appendix.
Intestinal transplantation is a complex technical procedure that provides patients suffering from end-stage intestinal failure an opportunity to enjoy improved quality of life, nutrition and survival. Compared to other types of organ transplants, it is a relatively new advancement in the field of organ transplantation. Nevertheless, great advances have been made over the past few decades to the present era, including the use of ischemic preconditioning, gene therapy, and addition of pharmacological supplements to preservation solutions. However, despite these strides, intestinal transplantation is still a challenging endeavor due to several factors. Notable among them is ischemia-reperfusion injury (IRI), which results in loss of cellular integrity and mucosal barrier function. In addition, IRI causes graft failure, delayed graft function, and decreased graft and recipient survival. This has necessitated the search for novel therapeutic avenues and improved transplantation protocols to prevent or attenuate intestinal IRI. Among the many candidate agents that are being investigated to combat IRI and its associated complications, nitric oxide (NO). NO is an endogenously produced gaseous signaling molecule with several therapeutic properties. The purpose of this mini-review is to discuss IRI and its related complications in intestinal transplantation, and NO as an emerging pharmacological tool against this challenging pathological condition. i.
Participants who are six months postpartum will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless Electromyography (EMG) sensors will be used to record EMG and limb steadiness (via Inertial Measurement Units (IMU). Physical activity will be measured by questionnaire and accelerometer.
The present invention provides: a hydrogenated product of a block copolymer which has a low glass transition temperature and exhibits suitable flexibility, rubber elasticity, and elongation properties even in a low temperature range; a resin composition; and a method for producing the hydrogenated product of a block copolymer. The hydrogenated product of a block copolymer contains a polymer block (A) including a structural unit derived from an aromatic vinyl compound and a polymer block (B) including a structural unit derived from a conjugated diene compound. The hydrogenated product of a block copolymer satisfies conditions (1) to (3) indicated below. (1) The structural unit derived from a conjugated diene compound in the polymer block (B) has a structural unit derived from butadiene and a structural unit derived from isoprene, and does not have any structural units derived from farnesene. (2) The glass transition temperature of the hydrogenated product of a block copolymer is -50 DEG C or less. (3) When the weight average molecular weight of the hydrogenated product of a block copolymer is denoted by x and the crystallization temperature is denoted by y (DEG C), the hydrogenated product of a block copolymer satisfies 5.8x/100,000 - y > 17.
1. The subjects have to ingest 7 different dosages of either beetroot juice or sodium nitrate on seven different occasions. Every hour a blood withdrawal is taken to measure nitrate and nitrite concentration in the blood.
2. The subjects have to ingest 7 different dosages of either beetroot juice or sodium nitrate on seven different occasions. Three hours after the intake of the supplement the subjects have to perform an exercise test on a bicycle. They have to cycle 5 min at 50% of maximal oxygen consumption and 8min at 80% of maximal oxygen consumption separated by a 5min break. Oxygen consumption would be measured during the whole exercise test. Blood withdrawal is taken before the ingestion, after 3 hours and after the test.
Skeletal muscle plays an integral role in locomotion, but also as part of the integrative physiological system. Recent progress has identified crosstalk between skeletal muscle and various physiological systems, including the immune system. Both the musculoskeletal and immune systems are impacted by aging. Increased age is associated with decreased muscle mass and function, while the immune system undergoes "inflammaging" and immunosenescence. Exercise is identified as a preventative medicine that can mitigate loss of function for both systems. This review summarizes: (1) the inflammatory pathways active in skeletal muscle; and (2) the inflammatory and skeletal muscle response to unaccustomed exercise in younger and older adults. Compared to younger adults, it appears older individuals have a muted pro-inflammatory response and elevated anti-inflammatory response to exercise. This important difference could contribute to decreased regeneration and recovery following unaccustomed exercise in older adults, as well as in chronic disease. The current research provides specific information on the role inflammation plays in altering skeletal muscle form and function, and adaptation to exercise; however, the pursuit of more knowledge in this area will delineate specific interventions that may enhance skeletal muscle recovery and promote resiliency in this tissue particularly with aging.
Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
Primary Pulmonary Hypertension (PPH) \- a rare, frequently fatal disease of the lungs - has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.
Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
A method for altering the surface structure of ultra-disperse particles to allow predetermined interactions to take place in biological media. In a preferred embodiment of the invention, an ultra-disperse particle is subjected to particle modification, allowing the building of structures on the surface of a basically spherical particle so as to direct its interactions. The inventive method allows the building of protrusions of different shapes and different branching patterns, bonding of different chemicals and changing of electronic structure of the surface on the basically spherical particle.  Particle modification enables the formation of layers allowing sequential actions to be performed by the particle, or modification can create more than one type of interactive surface on each particle allowing different interactions to occur simultaneously. These modified particles have applications, for example, as pharmaceuticals, cosmetics, preservatives, and in many other fields. Water-oil emulsions can be created for use in skin creams and other cosmetic and food industry applications. The particles can be used in many applications involving radiation to reduce the level of radioactivity necessary, thereby lowering exposure. The particles have the ability to structure biological media by creating a three-sided biological system comprising a biological tissue, the particle and the surrounding liquid.
Imiquimod Cream should be applied once daily before bedtime to the skin of the affected area (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no-treatment period. Imiquimod Cream should be applied as a thin film to the entire treatment area and rubbed in until the cream is no longer visible. Up to 0.5 grams (two full actuations of the pump) of Imiquimod Cream may be applied to the treatment area at each application. Imiquimod Cream should be left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of Imiquimod Cream therapy.

Patients should wash their hands before and after applying Imiquimod Cream.

Avoid use in or on the lips and nostrils. Do not use in or near the eyes.

Local skin reactions in the treatment area are common [see Adverse Reactions (6.1)]. A rest period of several days may be taken if required by the patient’s discomfort or severity of the local skin reaction. However, neither 2-week treatment cycle should be extended due to missed doses or rest periods. A transient increase in lesion counts may be observed during treatment. Response to treatment cannot be adequately assessed until resolution of local skin reactions. The patient should continue dosing as prescribed. Treatment should continue for the full treatment course even if all actinic keratoses appear to be gone. Lesions that do not respond to treatment should be carefully re-evaluated and management reconsidered.

Prescribe no more than two 7.5 g pumps for the total 2-cycle treatment course.
Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
The present invention refers to a genetic construct for carrying a protein of interest in cyanobacterial extracellular vesicles (EVs) of Synechocystis sp. PCC6803. The present invention further relates to the derived transformed Synechocystis strain comprising the said construct. Cyanobacterium transformed with referred construct are, most surprisingly, further characterized by hypervesiculating EVs to larger extents than the wild-type and mutant strains known in the art. Cyanobacterium transformed with the referred construct secrete the protein of interest in EVs and to the extracellular medium thus, the present invention also refers to compositions comprising EVs derived from the said transformed Synechocystis strain, as well as compositions comprising the EV-free extracellular medium derived from the said transformed Synechocystis strain, for use in carrying proteins proteins/enzymes into animals, including mammals and fish. The present invention further refers to methods for transforming mammalian epithelial cells with EVs isolated from the said Synechocystis strain, which internalize the said EVs and display the protein of interest. Moreover, the present invention refers to methods by which cyanobacterial EVs can work as nanocarriers of custom proteins into fish, with prospective applications in modulation of nutritional status or stimulating specific adaptive immune responses. The construct, strain, compositions uses and methods in the present invention may be advantageously employed as a novel biotechnological tool for the specific delivery of biologically active proteins and enzymes in biotechnology in general and in aquaculture in specific.